URGN SEC Filings - Urogen Pharma 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides a comprehensive resource for Urogen Pharma (URGN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K material event reports, and insider trading forms. It aggregates regulatory disclosures for the Israel-organized biotechnology issuer listed on The Nasdaq Stock Market. The platform also offers AI-powered summaries, impact scoring, and sentiment analysis for each filing, helping investors quickly understand complex financial and governance information.
MAR 31·GlobeNewswire▲
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Pharma Ltd. announced the publication of pivotal Phase 3 ENVISION trial results for ZUSDURI™ (mitomycin) in The Journal of Urology. The study demonstrated a 72.2% probability of remaining event-free at 24 months after achieving a complete response at three months in adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). ZUSDURI, the first FDA-approved therapy for this condition, offers a non-surgical treatment potentially breaking the cycle of repeated recurrences and surgeries.
MAR 6·MarketBeat→
JPMorgan Chase & Co. Buys 144,181 Shares of Urogen Pharma $URGN
JPMorgan Chase & Co. increased its holdings in Urogen Pharma by 36.9% in the third quarter, acquiring an additional 144,181 shares, bringing its total to 534,545 shares valued at approximately $10.66 million. Despite strong institutional ownership at 91.29% and a recent EPS beat, insiders like Mark Schoenberg and the General Counsel have been selling shares. The company faces mixed analyst sentiment, with a "Moderate Buy" average rating but also substantial lowering of near-term EPS estimates by some analysts.
